

Table S1. Supporting data for anthropometric parameters of participants during the 4-week trial (Table 3).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|---------------------------------|----------|----------|---------------|----------|---|------------------|
| | Start | End | Start | End | Start | End |
| Body weight (kg) | | | | | | |
| BS then placebo | 63.9±4.0 | 64.5±4.1 | 63.8±4.1 | 63.6±4.1 | -0.2 | -0.9 |
| Placebo then BS | 63.7±4.0 | 64.0±4.0 | 64.2±3.9 | 64.2±3.8 | 0.5 | 0.2 |
| Treatment effect | - | - | - | - | -0.2 | -0.4 |
| 95% confidence interval | | | | | -7.5 to 8.4 | -8.2 to 7.5 |
| Welch's t test | | | | | <i>p</i> =0.9105 | <i>p</i> =0.9250 |
| BMI | | | | | | |
| BS then placebo | 22.7±1.1 | 22.9±1.1 | 22.6±1.1 | 22.6±1.1 | -0.1 | -0.3 |
| Placebo then BS | 23.4±1.4 | 23.5±1.4 | 23.6±1.3 | 23.6±1.3 | 0.2 | 0.1 |
| Treatment effect | - | - | - | - | 0.1 | -0.1 |
| 95% confidence interval | | | | | -2.2 to 2.6 | -2.5 to 2.3 |
| Welch's t test | | | | | <i>p</i> =0.5523 | <i>p</i> =0.4584 |
| Body fat (%) | | | | | | |
| BS then placebo | 23.9±2.0 | 24.9±1.9 | 23.5±2.1 | 23.7±2.0 | -0.4 | -1.3 |
| Placebo then BS | 23.8±2.9 | 25.8±2.6 | 25.1±2.9 | 25.0±2.9 | 1.3 | -0.8 |
| Treatment effect | - | - | - | - | 0.4 | -1.0 |
| 95% confidence interval | | | | | -3.2 to 6.2 | -5.8 to 3.7 |
| Welch's t test | | | | | <i>p</i> =0.7348 | <i>p</i> =0.3328 |
| Visceral fat (%) | | | | | | |
| BS then placebo | 8.5±1.5 | 9.0±1.6 | 8.5±1.5 | 8.5±1.6 | -0.1 | -0.5 |
| Placebo then BS | 8.2±1.4 | 7.7±1.4 | 8.5±1.4 | 8.5±1.4 | 0.4 | 0.8 |
| Treatment effect | - | - | - | - | 0.1 | 0.2 |
| 95% confidence interval | | | 8.5±1.4 | | -2.7 to 3.0 | -2.8 to 3.1 |
| Welch's t test | | | | | <i>p</i> =0.9234 | <i>p</i> =0.5494 |
| Biological age | | | | | | |
| BS then placebo | 36.0±3.3 | 37.3±3.4 | 35.5±3.1 | 35.5±3.4 | -0.5 | -1.7 |
| Placebo then BS | 36.5±4.8 | 37.4±4.7 | 38.7±4.8 | 38.5±4.8 | 2.2 | 1.2 |
| Treatment effect | - | - | - | - | 0.9 | -0.3 |
| 95% confidence interval | | | | | -4.1 to 17.2 | -8.4 to 7.9 |
| Welch's t test | | | | | <i>p</i> =0.8886 | <i>p</i> =0.4733 |
| Basal metabolic rate (kcal/day) | | | | | | |
| BS then placebo | 1375±82 | 1371±81 | 1378±84 | 1370±81 | 3.6 | -1.0 |
| Placebo then BS | 1361±73 | 1350±72 | 1355±71 | 1354±68 | -6.5 | 4.7 |
| Treatment effect | - | - | - | - | -1.5 | 1.9 |
| 95% confidence interval | | | | | -154.9 to 152.0 | -147.9 to 151.6 |
| Welch's t test | | | | | <i>p</i> =0.9801 | <i>p</i> =0.9848 |

| | | | | | | | |
|--------------------------|----------|----------|----------|----------|------------------|------------------|--|
| Estimated bone mass (kg) | | | | | | | |
| BS then placebo | 2.6±0.2 | 2.6±0.2 | 2.6±0.1 | 2.6±0.2 | 0 | 0 | |
| Placebo then BS | 2.6±0.1 | 2.7±0.1 | 2.6±0.1 | 2.6±0.1 | 0 | -0.1 | |
| Treatment effect | - | - | - | - | 0 | 0 | |
| 95% confidence interval | | | | | -0.28 to 0.27 | -0.30 to 0.24 | |
| Welch's t test | | | | | <i>p</i> =0.8404 | <i>p</i> =0.947 | |
| Muscle mass (%) | | | | | | | |
| BS then placebo | 46.0±3.2 | 45.8±3.1 | 46.2±3.2 | 45.9±3.1 | 0.1 | 0.1 | |
| Placebo then BS | 45.5±2.8 | 44.4±2.7 | 45.1±2.7 | 45.2±2.7 | -0.3 | 0.7 | |
| Treatment effect | - | - | - | - | -0.1 | 0.4 | |
| 95% confidence interval | | | | | -6.0 to 5.8 | -5.3 to 6.2 | |
| Welch's t test | | | | | <i>p</i> =0.8893 | <i>p</i> =0.9766 | |

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.

Table S2. Supporting data for the effect of black soybean consumption on the vascular function (Table 4).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|-------------------------|-----------|-----------|---------------|-----------|---|------------------|
| | Start | End | Start | End | Start | End |
| Vascular function | | | | | | |
| BS then placebo | 52.0±3.1 | 52.3±2.9 | 54.1±3.8 | 50.9±3.4 | 2.1 | -1.4 |
| Placebo then BS | 53.1±3.2 | 52.1±3.7 | 50.3±3.3 | 47.7±2.8 | -2.8 | -4.4 |
| Treatment effect | - | - | - | - | -0.4 | -2.9 |
| 95% confidence interval | | | | | -6.3 to 7.0 | -3.6 to 9.3 |
| Welch's t test | | | | | <i>p</i> =0.5439 | <i>p</i> =0.0312 |
| <i>a</i> wave | | | | | | |
| BS then placebo | 110.2±1.1 | 109.8±1.1 | 114.9±3.4 | 114.7±2.0 | 4.7 | 4.9 |
| Placebo then BS | 107.8±3.4 | 116.1±2.5 | 107.4±3.7 | 103.8±3.0 | -0.5 | -12.3 |
| Treatment effect | - | - | - | - | 2.1 | -3.7 |
| 95% confidence interval | | | | | -8.5 to 4.2 | -1.6 to 8.9 |
| Welch's t test | | | | | <i>p</i> =0.5027 | <i>p</i> =0.1656 |
| <i>b</i> wave | | | | | | |
| BS then placebo | -59.2±3.9 | -54.1±5.1 | -59.5±4.8 | -62.9±3.4 | -0.4 | -8.8 |
| Placebo then BS | -56.5±5.4 | -63.9±5.1 | -57.6±4.3 | -61.7±2.6 | -1.2 | 2.2 |
| Treatment effect | - | - | - | - | -0.8 | -3.3 |
| 95% confidence interval | | | | | -8.4 to 10.0 | -5.3 to 10.0 |
| Welch's t test | | | | | <i>p</i> =0.866 | <i>p</i> =0.4406 |
| <i>c</i> wave | | | | | | |
| BS then placebo | -32.2±6.3 | -30.5±7.9 | -43.3±5.3 | -31.7±5.3 | -11.1 | -1.3 |
| Placebo then BS | -32.2±6.0 | -42.2±7.1 | -28.5±4.9 | -22.8±4.2 | 3.6 | 19.4 |
| Treatment effect | - | - | - | - | -3.7 | 9.0 |
| 95% confidence interval | | | | | -7.9 to 15.3 | -21.9 to 3.8 |

| | | | | | | |
|----------------------------|-----------|-----------|-----------|-----------|------------------|------------------|
| Welch's t test | | | | | <i>p</i> =0.5196 | <i>p</i> =0.1619 |
| <i>d</i> wave | | | | | | |
| BS then placebo | -49.5±6.8 | -51.6±7.7 | -66.6±6.3 | -51.3±5.2 | -17.2 | 0.4 |
| Placebo then BS | -51.3±5.9 | -58.6±8.9 | -45.5±6.0 | -37.0±3.9 | 5.7 | 21.6 |
| Treatment effect | - | - | - | - | -5.7 | 11.0 |
| 95% confidence interval | | | | | -7.4 to 18.9 | -24.7 to 2.7 |
| Welch's t test | | | | | <i>p</i> =0.3863 | <i>p</i> =0.056 |
| Vascular waveform | | | | | | |
| BS then placebo | 3.8±0.3 | 3.9±0.5 | 4.4±0.5 | 3.5±0.4 | 0.5 | -0.4 |
| Placebo then BS | 3.8±0.4 | 3.7±0.4 | 3.2±0.4 | 2.6±0.3 | -0.6 | -1.1 |
| Treatment effect | - | - | - | - | 0 | -0.7 |
| 95% confidence interval | | | | | -0.8 to 0.9 | -0.1 to 1.5 |
| Welch's t test | | | | | <i>p</i> =0.9171 | <i>p</i> =0.0392 |
| Waveform score | | | | | | |
| BS then placebo | 44.2±2.9 | 43.1±5.3 | 37.7±4.2 | 47.5±3.5 | -6.5 | 4.4 |
| Placebo then BS | 44.7±3.9 | 44.5±3.8 | 49.4±4.0 | 54.6±2.9 | 4.6 | 10.2 |
| Treatment effect | - | - | - | - | -0.9 | 7.3 |
| 95% confidence interval | | | | | -15.3 to 0.7 | -7.0 to 8.8 |
| Welch's t test | | | | | <i>p</i> =0.9171 | <i>p</i> =0.0368 |
| Peripheral vascular health | | | | | | |
| BS then placebo | 64.0±3.6 | 61.6±6.0 | 56.2±2.9 | 65.1±3.2 | -7.8 | 9.2 |
| Placebo then BS | 60.0±4.9 | 59.6±4.2 | 69.2±2.2 | 74.8±2.7 | 3.5 | 15.2 |
| Treatment effect | - | - | - | - | 0.7 | 9.3 |
| 95% confidence interval | | | | | -17.9 to -0.7 | -8.3 to 6.9 |
| Welch's t test | | | | | <i>p</i> =0.8569 | <i>p</i> =0.017 |
| Blood pressure | | | | | | |
| Systolic blood pressure | | | | | | |
| BS then placebo | 119.9±5.4 | 127.5±4.4 | 128.0±5.0 | 116.5±4.4 | 8.1 | -11.0 |
| Placebo then BS | 124.3±4.1 | 123.8±2.9 | 129.1±4.8 | 127.2±3.6 | 4.8 | 3.4 |
| Treatment effect | - | - | - | - | 6.4 | -3.8 |
| 95% confidence interval | | | | | -13.0 to -0.3 | -4.1 to 17.2 |
| Welch's t test | | | | | <i>p</i> =0.2229 | <i>p</i> =0.0392 |
| Diastolic blood pressure | | | | | | |
| BS then placebo | 78.2±3.1 | 83.5±3.2 | 85.9±4.3 | 77.4±3.2 | 7.7 | -6.1 |
| Placebo then BS | 84.2±2.9 | 81.6±3.6 | 83.2±3.7 | 84.5±2.2 | -1.0 | 2.8 |
| Treatment effect | - | - | - | - | 3.4 | -1.6 |
| 95% confidence interval | | | | | -3.7 to 10.7 | -8.0 to 4.7 |
| Welch's t test | | | | | <i>p</i> =0.6039 | <i>p</i> =0.33 |
| Central blood pressure | | | | | | |
| BS then placebo | 126.6±5.8 | 133.6±4.2 | 134.7±5.7 | 123.3±4.7 | 8.1 | -10.4 |
| Placebo then BS | 132.2±4.2 | 131.6±5.2 | 133.4±6.8 | 132.0±4.3 | 1.2 | 0.4 |

| | | | | | | |
|-------------------------|---|---|---|---|------------------|------------------|
| Treatment effect | - | - | - | - | 4.6 | -5.0 |
| 95% confidence interval | | | | | -14.4 to 4.3 | -6.7 to 16.0 |
| Welch's t test | | | | | <i>p</i> =0.4133 | <i>p</i> =0.2844 |

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.

Table S3. Supporting data for the effect of black soybean consumption on the antioxidant activity (Table 5).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|---------------------------------------|-----------|----------|---------------|-----------|---|------------------|
| | Start | End | Start | End | Start | End |
| Plasma | | | | | | |
| NO ₂ /NO ₃ (μM) | | | | | | |
| BS then placebo | 36.9±4.7 | 28.7±2.1 | 26.7±3.3 | 41.9±5.0 | -10.2 | 13.1 |
| Placebo then BS | 21.4±4.9 | 30.4±1.9 | 31.4±4.4 | 28.9±2.4 | 10.1 | -1.5 |
| Treatment effect | - | - | - | - | -0.1 | 5.8 |
| 95% confidence interval | | | | | -9.1 to 9.8 | -1.4 to 12.4 |
| Welch's t test | | | | | <i>p</i> =0.9467 | <i>p</i> =0.048 |
| HEL (nM) | | | | | | |
| BS then placebo | 4.7±0.2 | 4.5±0.2 | 3.9±0.1 | 4.6±0.3 | -0.8 | 0.2 |
| Placebo then BS | 3.9±0.2 | 4.7±0.2 | 4.7±0.3 | 4.3±0.2 | 0.8 | -0.4 |
| Treatment effect | - | - | - | - | 0 | -0.1 |
| 95% confidence interval | | | | | -0.4 to 0.5 | -0.6 to 0.4 |
| Welch's t test | | | | | <i>p</i> =0.858 | <i>p</i> =0.6632 |
| MPO (ng/mL) | | | | | | |
| BS then placebo | 88.3±4.5 | 95.7±6.2 | 88.1±5.0 | 79.7±3.1 | -0.2 | -16.1 |
| Placebo then BS | 87.8±3.9 | 85.4±3.6 | 85.1±3.4 | 90.2±3.7 | -2.8 | 4.8 |
| Treatment effect | - | - | - | - | -1.5 | -5.6 |
| 95% confidence interval | | | | | -10.0 to 7.0 | -14.4 to 4.2 |
| Welch's t test | | | | | <i>p</i> =0.727 | <i>p</i> =0.272 |
| 8-OHdG (ng/mL) | | | | | | |
| BS then placebo | 1.8±0.3 | 1.4±0.1 | 1.8±0.1 | 1.4±0.1 | 0 | 0 |
| Placebo then BS | 1.5±0.1 | 1.7±0.1 | 1.4±0.0 | 1.2±0.0 | -0.1 | -0.5 |
| Treatment effect | - | - | - | - | 4.6 | -0.3 |
| 95% confidence interval | | | | | -0.4 to 0.2 | -0.4 to -0.04 |
| Welch's t test | | | | | <i>p</i> =0.354 | <i>p</i> =0.011 |
| Urine | | | | | | |
| NO ₂ /NO ₃ (μM) | | | | | | |
| BS then placebo | 28.2±10.1 | 16.8±5.6 | 22.2±6.2 | 28.9±10.8 | -0.6 | 12.1 |
| Placebo then BS | 14.3±3.7 | 14.2±4.3 | 15.3±6.1 | 34.2±10.5 | 1.1 | 20 |
| Treatment effect | - | - | - | - | -2.5 | 16 |
| 95% confidence interval | | | | | -16.3 to 12.0 | -0.6 to 32.7 |
| Welch's t test | | | | | <i>p</i> =0.762 | <i>p</i> =0.029 |

| | | | | | | | |
|-------------------------|------------|------------|------------|------------|---|-----------------|-----------------|
| HEL (nM) | | | | | | | |
| BS then placebo | 108.0±34.2 | 83.2±20.0 | 136.1±35.7 | 103.4±15.4 | | 28.1 | 20.2 |
| Placebo then BS | 112.7±48.7 | 161.7±79.9 | 120.1±28.6 | 124.7±26.4 | | 7.4 | -37.1 |
| Treatment effect | - | - | - | - | - | 17.8 | -8.4 |
| 95% confidence interval | | | | | | -58.5 to 94.6 | -98.1 to 82.3 |
| Welch's t test | | | | | | <i>p</i> =0.636 | <i>p</i> =0.858 |
| MPO (ng/mL) | | | | | | | |
| BS then placebo | 10.2±0.1 | 17.7±7.7 | 10.1±0.1 | 10.3±0.2 | | -0.1 | -7.5 |
| Placebo then BS | 10.8±0.7 | 10.2±0.1 | 10.1±0.1 | 9.9±0.0 | | -0.7 | -0.3 |
| Treatment effect | - | - | - | - | - | -0.4 | -3.9 |
| 95% confidence interval | | | | | | -1.1 to 0.3 | -11.9 to 4.1 |
| Welch's t test | | | | | | <i>p</i> =0.277 | <i>p</i> =0.326 |
| 8-OHdG (ng/mL) | | | | | | | |
| BS then placebo | 7.6±1.6 | 15.1±4.6 | 8.3±2.2 | 8.0±0.9 | | 0.7 | -7.0 |
| Placebo then BS | 11.1±2.9 | 9.9±2.2 | 7.0±2.1 | 10.9±1.1 | | -1.6 | -2.9 |
| Treatment effect | - | - | - | - | - | -0.5 | -5.0 |
| 95% confidence interval | | | | | | -5.2 to 4.1 | -10.4 to 0.6 |
| Welch's t test | | | | | | <i>p</i> =0.403 | <i>p</i> =0.039 |

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.

Table S4. Supporting data for the effect of black soybean consumption on polyphenol concentration in the plasma (Figure 1).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|-------------------------|-------------|-------------|---------------|-------------|---|-----------------|
| | Start | End | Start | End | Start | End |
| (-)-Epicatechin (nM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 1.15±0.16 | 0.90±0.18 | 0.79±0.15 | 1.52±0.38 | -0.36 | 0.62 |
| Placebo then BS | 2.60±0.51 | 2.64±0.57 | 2.51±0.43 | 3.63±0.59 | -0.09 | 0.99 |
| Treatment effect | - | - | - | - | -0.23 | 0.81 |
| 95% confidence interval | | | | | -1.4 to 0.8 | 0.2 to 1.8 |
| Welch's t test | | | | | <i>p</i> =0.613 | <i>p</i> =0.104 |
| Conjugates | | | | | | |
| BS then placebo | 0.51±0.13 | 0.67±0.18 | 0.64±0.13 | 1.80±0.60 | 0.13 | 1.14 |
| Placebo then BS | 1.30±0.54 | 1.33±0.34 | 0.68±0.19 | 2.11±0.71 | -0.62 | 0.78 |
| Treatment effect | - | - | - | - | -0.24 | 0.96 |
| 95% confidence interval | | | | | -11.7 to 5.8 | -0.5 to 10.2 |
| Welch's t test | | | | | <i>p</i> =0.490 | <i>p</i> =0.075 |
| Daidzein (nM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 0.008±0.002 | 0.007±0.002 | 0.005±0.002 | 0.015±0.004 | -0.003 | 0.008 |
| Placebo then BS | 0.009±0.003 | 0.004±0.001 | 0.008±0.002 | 0.014±0.003 | -0.001 | 0.01 |
| Treatment effect | - | - | - | - | -0.002 | 0.009 |

| | | | | | | | | |
|-------------------------|-------------|-------------|-------------|-------------|--|---|------------------|-----------------|
| 95% confidence interval | | | | | | - | -5.8 to 6.2 | 2.6 to 14.6 |
| Welch's t test | | | | | | | <i>p</i> =0.9996 | <i>p</i> =0.002 |
| Conjugates | | | | | | | | |
| BS then placebo | 0.005±0.003 | 0.007±0.003 | 0.005±0.002 | 0.061±0.025 | | | 0 | 0.054 |
| Placebo then BS | 0.013±0.006 | 0.007±0.002 | 0.016±0.009 | 0.023±0.007 | | | 0.003 | 0.016 |
| Treatment effect | - | - | - | - | | | 0.002 | 0.035 |
| 95% confidence interval | | | | | | | -23.4 to 31.2 | 10.7 to 65.3 |
| Welch's t test | | | | | | | <i>p</i> =0.999 | <i>p</i> =0.003 |
| Genistein (nM) | | | | | | | | |
| Aglycone | | | | | | | | |
| BS then placebo | 0.002±0.001 | 0.002±0.001 | 0.005±0.002 | 0.005±0.001 | | | 0.003 | 0.003 |
| Placebo then BS | 0.005±0.004 | 0.006±0.005 | 0.008±0.006 | 0.010±0.006 | | | 0.003 | 0.004 |
| Treatment effect | - | - | - | - | | | 0.003 | 0.004 |
| 95% confidence interval | | | | | | | -15.7 to 20.2 | -16.8 to 19.1 |
| Welch's t test | | | | | | | <i>p</i> =0.988 | <i>p</i> =0.998 |
| Conjugates | | | | | | | | |
| BS then placebo | 0.088±0.051 | 0.101±0.048 | 0.039±0.021 | 0.225±0.061 | | | -0.049 | 0.124 |
| Placebo then BS | 0.050±0.014 | 0.040±0.014 | 0.056±0.017 | 0.110±0.030 | | | 0.006 | 0.07 |
| Treatment effect | - | - | - | - | | | -0.022 | 0.097 |
| 95% confidence interval | | | | | | | -59.4 to 125.6 | 5.4 to 190.4 |
| Welch's t test | | | | | | | <i>p</i> =0.780 | <i>p</i> =0.002 |
| Glycitein (nM) | | | | | | | | |
| Aglycone | | | | | | | | |
| BS then placebo | 0.005±0.001 | 0.008±0.002 | 0.005±0.002 | 0.007±0.002 | | | 0 | -0.001 |
| Placebo then BS | 0.005±0.001 | 0.003±0.001 | 0.004±0.001 | 0.006±0.001 | | | -0.001 | 0.003 |
| Treatment effect | - | - | - | - | | | -0.001 | 0.001 |
| 95% confidence interval | | | | | | | -3.2 to 3.2 | -1.8 to 4.7 |
| Welch's t test | | | | | | | <i>p</i> =1.000 | <i>p</i> =0.636 |
| Conjugates | | | | | | | | |
| BS then placebo | 0.004±0.002 | 0.003±0.002 | 0.004±0.002 | 0.008±0.004 | | | 0 | 0.005 |
| Placebo then BS | 0.002±0.001 | 0.001±0.001 | 0.002±0.001 | 0.003±0.001 | | | 0 | 0.002 |
| Treatment effect | - | - | - | - | | | 0 | 0.004 |
| 95% confidence interval | | | | | | | -5.2 to 5.4 | -1.1 to 9.5 |
| Welch's t test | | | | | | | <i>p</i> =1.000 | <i>p</i> =0.164 |
| (S)-Equol (µM) | | | | | | | | |
| Aglycone | | | | | | | | |
| BS then placebo | 0.002±0.002 | 0.001±0.001 | 0.010±0.004 | 0.013±0.004 | | | 0.008 | 0.012 |
| Placebo then BS | 0.006±0.002 | 0.003±0.001 | 0.003±0.001 | 0.008±0.002 | | | -0.003 | 0.005 |
| Treatment effect | - | - | - | - | | | 0.003 | 0.009 |
| 95% confidence interval | | | | | | | -2.8 to 8.4 | 0.4 to 11.5 |
| Welch's t test | | | | | | | <i>p</i> =0.549 | <i>p</i> =0.031 |
| Conjugates | | | | | | | | |
| BS then placebo | 0.016±0.015 | 0.018±0.013 | 0.008±0.006 | 0.058±0.047 | | | -0.008 | 0.04 |
| Placebo then BS | 0.005±0.004 | 0.002±0.001 | 0.010±0.005 | 0.014±0.004 | | | 0.005 | 0.012 |
| Treatment effect | - | - | - | - | | | -0.002 | 0.026 |

95% confidence interval
Welch's t test

-38.3 to 43.0
 $p=0.999$

-10.9 to 70.4
 $p=0.225$

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.

Table S5A. Supporting data for the effect of black soybean consumption on polyphenol concentration in the urine (Figure 2).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|-------------------------|-------------------|-------------------|-------------------|-------------------|---|----------------|
| | Start | End | Start | End | Start | End |
| C3G (μM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 1.781 \pm 0.231 | 2.083 \pm 0.336 | 1.421 \pm 0.204 | 2.927 \pm 1.224 | -0.36 | 0.844 |
| Placebo then BS | 1.518 \pm 0.223 | 1.797 \pm 0.271 | 1.260 \pm 0.187 | 2.315 \pm 0.365 | -0.258 | 0.518 |
| Treatment effect | - | - | - | - | -0.309 | 0.681 |
| 95% confidence interval | | | | | -0.73 to 0.11 | -0.68 to 2.04 |
| Welch's t test | | | | | $p=0.148$ | $p=0.313$ |
| Conjugates | | | | | | |
| BS then placebo | 0.189 \pm 0.069 | 0.697 \pm 0.191 | 0.334 \pm 0.146 | 0.667 \pm 0.217 | 0.145 | -0.03 |
| Placebo then BS | 0.323 \pm 0.060 | 0.430 \pm 0.227 | 0.278 \pm 0.053 | 0.384 \pm 0.125 | -0.045 | -0.046 |
| Treatment effect | - | - | - | - | 0.050 | -0.038 |
| 95% confidence interval | | | | | -0.13 to 0.23 | -0.43 to 0.35 |
| Welch's t test | | | | | $p=0.579$ | $p=0.846$ |
| (-)-Epicatechin (nM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 0.349 \pm 0.117 | 0.383 \pm 0.073 | 0.292 \pm 0.063 | 1.316 \pm 0.754 | -0.057 | 0.933 |
| Placebo then BS | 0.395 \pm 0.101 | 0.685 \pm 0.232 | 0.453 \pm 0.075 | 0.698 \pm 0.118 | 0.058 | 0.013 |
| Treatment effect | - | - | - | - | 0.001 | 0.473 |
| 95% confidence interval | | | | | -0.18 to 0.18 | -0.35 to 1.29 |
| Welch's t test | | | | | $p=0.999$ | $p=0.251$ |
| Conjugates | | | | | | |
| BS then placebo | 0.223 \pm 0.125 | 0.360 \pm 0.088 | 0.532 \pm 0.224 | 1.442 \pm 0.816 | 0.309 | 1.082 |
| Placebo then BS | 0.221 \pm 0.078 | 0.249 \pm 0.085 | 0.228 \pm 0.059 | 0.490 \pm 0.189 | 0.007 | 0.241 |
| Treatment effect | - | - | - | - | 0.158 | 0.662 |
| 95% confidence interval | | | | | -0.14 to 0.46 | -0.22 to 1.54 |
| Welch's t test | | | | | $p=0.286$ | $p=0.135$ |
| Procyanidin B2 (nM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 0.101 \pm 0.054 | 0.076 \pm 0.018 | 0.032 \pm 0.005 | 0.130 \pm 0.041 | -0.069 | 0.054 |
| Placebo then BS | 0.052 \pm 0.007 | 0.045 \pm 0.012 | 0.052 \pm 0.008 | 0.100 \pm 0.020 | 0 | 0.055 |
| Treatment effect | - | - | - | - | -0.035 | 0.055 |
| 95% confidence interval | | | | | -0.09 to 0.02 | 0.003 to 0.105 |
| Welch's t test | | | | | $p=0.333$ | $p=0.211$ |
| Conjugates | | | | | | |
| BS then placebo | 0.062 \pm 0.026 | 0.071 \pm 0.025 | 0.022 \pm 0.010 | 0.072 \pm 0.045 | -0.04 | 0.001 |

| | | | | | | | |
|-------------------------|----------------|----------------|----------------|----------------|---|------------------|------------------|
| Placebo then BS | 0.011 ±0.002 | 0.020 ±0.005 | 0.021 ±0.006 | 0.099 ±0.035 | | 0.01 | 0.079 |
| Treatment effect | - | - | - | - | - | -0.015 | 0.04 |
| 95% confidence interval | | | | | | -0.05 to 0.02 | -0.02 to 0.10 |
| Welch's t test | | | | | | p=0.222 | p=0.038 |
| Procyanidin C1 (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 0.009 ±0.003 | 0.008 ±0.002 | 0.009 ±0.002 | 0.024 ±0.012 | | 0 | 0.016 |
| Placebo then BS | 0.010 ±0.003 | 0.014 ±0.004 | 0.009 ±0.003 | 0.016 ±0.003 | | -0.001 | 0.002 |
| Treatment effect | - | - | - | - | - | -0.001 | 0.009 |
| 95% confidence interval | | | | | | -0.005 to 0.005 | -0.004 to 0.02 |
| Welch's t test | | | | | | p=0.972 | p=0.180 |
| Conjugates | | | | | | | |
| BS then placebo | 0.002 ±0.001 | 0.003 ±0.001 | 0.008 ±0.007 | 0.015 ±0.010 | | 0.006 | 0.012 |
| Placebo then BS | 0.003 ±0.001 | 0.003 ±0.001 | 0.003 ±0.002 | 0.004 ±0.001 | | 0 | 0.001 |
| Treatment effect | - | - | - | - | - | 0.003 | 0.007 |
| 95% confidence interval | | | | | | -0.005 to 0.010 | -0.004 to 0.017 |
| Welch's t test | | | | | | p=0.479 | p=0.208 |
| Cinnamtannin A2 (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 0.0005 ±0.0002 | 0.0003 ±0.0001 | 0.0014 ±0.0006 | 0.0030 ±0.0010 | | 0.0009 | 0.0027 |
| Placebo then BS | 0.0007 ±0.0003 | 0.0016 ±0.0011 | 0.0007 ±0.0003 | 0.0006 ±0.0001 | | 0 | -0.001 |
| Treatment effect | - | - | - | - | - | 0.0005 | 0.0009 |
| 95% confidence interval | | | | | | -0.001 to 0.001 | -0.002 to 0.001 |
| Welch's t test | | | | | | p=0.630 | p=0.282 |
| Conjugates | | | | | | | |
| BS then placebo | 0.0001 ±0.0001 | 0.0002 ±0.0001 | 0.0014 ±0.0011 | 0.0010 ±0.0006 | | 0.0013 | 0.0008 |
| Placebo then BS | 0.0002 ±0.0001 | 0.0001 ±0.0001 | 0.004 ±0.0002 | 0.0002 ±0.0001 | | 0.0002 | 0.0001 |
| Treatment effect | - | - | - | - | - | 0.0008 | 0.0004 |
| 95% confidence interval | | | | | | 0.0003 to 0.0016 | 0.0004 to 0.0029 |
| Welch's t test | | | | | | p=0.008 | p=0.011 |

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.

Table S5B. Supporting data for the effect of black soybean consumption on polyphenol concentration in the urine (Figure 2).

| Test material | Placebo | | Black soybean | | within-individual difference: BS-Placebo | |
|-------------------------|--------------|--------------|---------------|--------------|---|-------------------|
| | Start | End | Start | End | Start | End |
| Daidzin (nM) | | | | | | |
| Aglycone | | | | | | |
| BS then placebo | 0.028 ±0.006 | 0.024 ±0.004 | 0.023 ±0.008 | 0.042 ±0.012 | -0.005 | 0.018 |
| Placebo then BS | 0.025 ±0.004 | 0.021 ±0.006 | 0.012 ±0.003 | 0.025 ±0.005 | -0.013 | -0.004 |
| Treatment effect | - | - | - | - | -0.009 | 0.007 |
| 95% confidence interval | | | | | -0.0199 to 0.0013 | -0.0038 to 0.0243 |

| | | | | | | | |
|-------------------------|--------------|--------------|--------------|---------------|---|-------------------|-------------------|
| Welch's t test | | | | | | <i>p</i> =0.083 | <i>p</i> =0.145 |
| Conjugates | | | | | | | |
| BS then placebo | 0.026±0.014 | 0.029±0.011 | 0.065±0.046 | 0.180±0.071 | | 0.039 | 0.151 |
| Placebo then BS | 0.036±0.019 | 0.023±0.008 | 0.039±0.021 | 0.289±0.097 | | 0.003 | 0.266 |
| Treatment effect | - | - | - | - | - | 0.021 | 0.209 |
| 95% confidence interval | | | | | | -0.034 to 0.073 | 0.083 to 0.344 |
| Welch's t test | | | | | | <i>p</i> =0.466 | <i>p</i> =0.999 |
| Genistin (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 0.005±0.003 | 0.002±0.002 | 0.002±0.001 | 0.017±0.007 | | -0.003 | 0.015 |
| Placebo then BS | 0.001±0.001 | 0.002±0.002 | 0.002±0.002 | 0.005±0.002 | | -0.001 | 0.003 |
| Treatment effect | - | - | - | - | - | -0.002 | 0.009 |
| 95% confidence interval | | | | | | -0.0046 to 0.0036 | 0.0005 to 0.0161 |
| Welch's t test | | | | | | <i>p</i> =0.811 | <i>p</i> =0.037 |
| Conjugates | | | | | | | |
| BS then placebo | 0.037±0.031 | 0.041±0.040 | 0.003±0.002 | 0.203±0.105 | | -0.034 | 0.162 |
| Placebo then BS | 0.021±0.011 | 0.013±0.006 | 0.010±0.005 | 0.452±0.282 | | -0.011 | 0.439 |
| Treatment effect | - | - | - | - | - | -0.023 | 0.301 |
| 95% confidence interval | | | | | | -0.0533 to 0.0099 | -0.0242 to 0.6520 |
| Welch's t test | | | | | | <i>p</i> =0.167 | <i>p</i> =0.067 |
| Glycitin (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 0.074±0.018 | 0.087±0.019 | 0.108±0.025 | 0.152±0.056 | | 0.034 | 0.065 |
| Placebo then BS | 0.070±0.017 | 0.076±0.013 | 0.040±0.010 | 0.150±0.031 | | -0.03 | 0.074 |
| Treatment effect | - | - | - | - | - | 0.002 | 0.07 |
| 95% confidence interval | | | | | | -0.0394 to 0.0365 | 0.0055 to 0.1349 |
| Welch's t test | | | | | | <i>p</i> =0.941 | <i>p</i> =0.035 |
| Conjugates | | | | | | | |
| BS then placebo | 0.058±0.021 | 0.024±0.014 | 0.120±0.076 | 0.141±0.056 | | 0.062 | 0.117 |
| Placebo then BS | 0.059±0.025 | 0.067±0.027 | 0.056±0.025 | 0.418±0.194 | | -0.003 | 0.351 |
| Treatment effect | - | - | - | - | - | -0.03 | 0.234 |
| 95% confidence interval | | | | | | -0.0556 to 0.1075 | 0.0095 to 0.4815 |
| Welch's t test | | | | | | <i>p</i> =0.518 | <i>p</i> =0.042 |
| Daidzein (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 3.124±1.171 | 1.288±5.538 | 2.435±0.588 | 10.426±3.921 | | -0.689 | 9.138 |
| Placebo then BS | 2.161±0.445 | 2.260±0.597 | 1.800±0.331 | 4.930±1.725 | | -0.361 | 2.67 |
| Treatment effect | - | - | - | - | - | -0.002 | 0.009 |
| 95% confidence interval | | | | | | -1.8449 to 0.8289 | 1.2599 to 9.9011 |
| Welch's t test | | | | | | <i>p</i> =0.443 | <i>p</i> =0.014 |
| Conjugates | | | | | | | |
| BS then placebo | 23.286±9.862 | 12.622±0.003 | 9.555±7.466 | 26.985±6.492 | | -13.731 | 14.363 |
| Placebo then BS | 13.287±5.173 | 13.962±8.289 | 20.650±4.753 | 40.633±12.576 | | 7.363 | 26.671 |
| Treatment effect | - | - | - | - | - | -3.184 | 20.517 |
| 95% confidence interval | | | | | | -15.782 to 11.523 | 2.7271 to 39.5389 |

| | | | | | | | |
|-------------------------|--------------|--------------|--------------|---------------|---|-------------------|-------------------|
| Welch's t test | | | | | | <i>p</i> =0.754 | <i>p</i> =0.026 |
| Genistein (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 1.669±0.710 | 0.973±0.280 | 0.831±0.273 | 4.850±1.657 | | -0.838 | 3.877 |
| Placebo then BS | 0.974±0.372 | 0.549±0.136 | 1.080±0.289 | 2.586±1.532 | | 0.106 | 2.037 |
| Treatment effect | - | - | - | - | - | -0.366 | 2.957 |
| 95% confidence interval | | | | | | -1.1889 to 0.5517 | 0.4948 to 5.2350 |
| Welch's t test | | | | | | <i>p</i> =0.460 | <i>p</i> =0.020 |
| Conjugates | | | | | | | |
| BS then placebo | 15.772±7.714 | 11.925±5.228 | 11.504±8.302 | 34.483±10.833 | | -4.286 | 22.558 |
| Placebo then BS | 8.103±2.888 | 7.213±2.894 | 10.041±1.942 | 40.772±12.587 | | 1.938 | 33.559 |
| Treatment effect | - | - | - | - | - | -1.174 | 28.059 |
| 95% confidence interval | | | | | | -11.687 to 9.978 | 10.528 to 46.689 |
| Welch's t test | | | | | | <i>p</i> =0.874 | <i>p</i> =0.001 |
| Glycitein (nM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 1.327±0.497 | 1.166±0.302 | 1.021±0.365 | 2.959±0.666 | | -0.306 | 1.793 |
| Placebo then BS | 1.254±0.398 | 1.928±0.620 | 0.801±0.167 | 3.032±0.781 | | -0.453 | 1.104 |
| Treatment effect | - | - | - | - | - | -0.38 | 1.449 |
| 95% confidence interval | | | | | | -1.1127 to 0.3386 | 0.1347 to 2.6937 |
| Welch's t test | | | | | | <i>p</i> =0.285 | <i>p</i> =0.031 |
| Conjugates | | | | | | | |
| BS then placebo | 4.554±1.809 | 6.379±2.974 | 3.554±2.728 | 20.283±5.996 | | -1.000 | 13.904 |
| Placebo then BS | 5.382±2.640 | 9.678±6.455 | 4.729±1.427 | 19.025±3.973 | | -0.653 | 9.347 |
| Treatment effect | - | - | - | - | - | -0.827 | 11.626 |
| 95% confidence interval | | | | | | -5.183 to 3.565 | 1.215 to 21.579 |
| Welch's t test | | | | | | <i>p</i> =0.710 | <i>p</i> =0.029 |
| (S)-Equol (µM) | | | | | | | |
| Aglycone | | | | | | | |
| BS then placebo | 0.477±0.227 | 0.313±0.099 | 0.227±0.069 | 0.368±0.117 | | -0.25 | 0.055 |
| Placebo then BS | 0.277±0.062 | 0.299±0.075 | 0.212±0.054 | 0.524±0.157 | | -0.065 | 0.225 |
| Treatment effect | - | - | - | - | - | -0.158 | 0.14 |
| 95% confidence interval | | | | | | -0.3846 to 0.0878 | -0.0887 to 0.3858 |
| Welch's t test | | | | | | <i>p</i> =0.207 | <i>p</i> =0.211 |
| Conjugates | | | | | | | |
| BS then placebo | 6.561±5.442 | 6.553±5.222 | 2.393±1.893 | 9.898±7.537 | | -4.168 | 3.345 |
| Placebo then BS | 1.061±0.432 | 0.813±0.231 | 1.126±0.481 | 4.815±2.862 | | 0.065 | 4.002 |
| Treatment effect | - | - | - | - | - | -2.052 | 3.674 |
| 95% confidence interval | | | | | | -7.2356 to 3.5553 | -5.186 to 12.599 |
| Welch's t test | | | | | | <i>p</i> =0.488 | <i>p</i> =0.402 |

BS; black soybean. Number of "BS then placebo" and "Placebo then BS" groups was 11 each and that of "Treatment effect" was 22.